293 related articles for article (PubMed ID: 37551274)
1. Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology.
Cao J; Zhang F; Xiong W
Int J Nanomedicine; 2023; 18():4421-4430. PubMed ID: 37551274
[TBL] [Abstract][Full Text] [Related]
2. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
Ng EW; Shima DT; Calias P; Cunningham ET; Guyer DR; Adamis AP
Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
[TBL] [Abstract][Full Text] [Related]
3. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Chong V
Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
[TBL] [Abstract][Full Text] [Related]
4. Pegaptanib for wet macular degeneration.
Fraunfelder FW
Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
[TBL] [Abstract][Full Text] [Related]
5. Pegaptanib for the treatment of age-related macular degeneration.
Zhou B; Wang B
Exp Eye Res; 2006 Sep; 83(3):615-9. PubMed ID: 16678158
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
7. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.
Ng EW; Adamis AP
Ann N Y Acad Sci; 2006 Oct; 1082():151-71. PubMed ID: 17145936
[TBL] [Abstract][Full Text] [Related]
8. Current status of anti-vascular endothelial growth factor therapy in Europe.
Wolf S
Jpn J Ophthalmol; 2008; 52(6):433-439. PubMed ID: 19089562
[TBL] [Abstract][Full Text] [Related]
9. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
10. [Results of an expert survey on VEGF inhibitors in ophthalmology].
Kühn T
Klin Monbl Augenheilkd; 2011 Jul; 228(7):607-12. PubMed ID: 21472638
[TBL] [Abstract][Full Text] [Related]
11. A review of clinical trials of anti-VEGF agents for diabetic retinopathy.
Nicholson BP; Schachat AP
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):915-30. PubMed ID: 20174816
[TBL] [Abstract][Full Text] [Related]
12. Pegaptanib sodium for ocular vascular disease.
Shukla D; Namperumalsamy P; Goldbaum M; Cunningham ET
Indian J Ophthalmol; 2007; 55(6):427-30. PubMed ID: 17951898
[TBL] [Abstract][Full Text] [Related]
13. Pegaptanib sodium for the treatment of age-related macular degeneration.
Apte RS
Expert Opin Pharmacother; 2008 Feb; 9(3):499-508. PubMed ID: 18220500
[TBL] [Abstract][Full Text] [Related]
14. Pegaptanib: a novel approach to ocular neovascularization.
Chapman JA; Beckey C
Ann Pharmacother; 2006; 40(7-8):1322-6. PubMed ID: 16849623
[TBL] [Abstract][Full Text] [Related]
15. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Ng EW; Adamis AP
Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
[TBL] [Abstract][Full Text] [Related]
16. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery.
Van Bergen T; Vandewalle E; Van de Veire S; Dewerchin M; Stassen JM; Moons L; Stalmans I
Exp Eye Res; 2011 Nov; 93(5):689-99. PubMed ID: 21907194
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.
Morjaria R; Chong NV
Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1185-92. PubMed ID: 24856361
[TBL] [Abstract][Full Text] [Related]
18. Aptamers: a new class of oligonucleotides in the drug discovery pipeline?
Dausse E; Da Rocha Gomes S; Toulmé JJ
Curr Opin Pharmacol; 2009 Oct; 9(5):602-7. PubMed ID: 19717337
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
20. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
